BH3 mimetics targeting BCL-XL have efficacy in solid tumors with RB1 loss and replication stress.
Saved in:
| Title: | BH3 mimetics targeting BCL-XL have efficacy in solid tumors with RB1 loss and replication stress. |
|---|---|
| Authors: | Varkaris A; Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.; Massachusetts General Cancer Center and Department of Medicine, Harvard Medical School, Boston, MA, USA., Wang K; Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.; Department of Urology, Union hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China., Nouri M; Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA., Kozlova N; Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA., Schmidt DR; Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA., Stavridi A; Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA., Arai S; Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA., Ambrosio N; Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA., Poluben L; Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA., Jimenez-Vacas JM; Institute of Cancer Research, Royal Marsden NHS Foundation Trust, London, UK., Westaby D; Institute of Cancer Research, Royal Marsden NHS Foundation Trust, London, UK., Carmichael J; Institute of Cancer Research, Royal Marsden NHS Foundation Trust, London, UK., Xie F; Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA., Figueiredo I; Institute of Cancer Research, Royal Marsden NHS Foundation Trust, London, UK., Buroni L; Institute of Cancer Research, Royal Marsden NHS Foundation Trust, London, UK., Neeb A; Institute of Cancer Research, Royal Marsden NHS Foundation Trust, London, UK., Gurel B; Institute of Cancer Research, Royal Marsden NHS Foundation Trust, London, UK., Chevalier N; Massachusetts General Cancer Center and Department of Medicine, Harvard Medical School, Boston, MA, USA., Brown L; Department of Urology, University of Washington, Seattle, WA, USA., Voznesensky O; Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA., Chen SY; Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA., Russo JW; Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA., Yuan X; Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA., Juric D; Massachusetts General Cancer Center and Department of Medicine, Harvard Medical School, Boston, MA, USA., Beltran H; Dana-Farber Cancer Institute, Boston, MA, USA., De Bono JS; Institute of Cancer Research, Royal Marsden NHS Foundation Trust, London, UK., Vander Heiden MG; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.; Dana-Farber Cancer Institute, Boston, MA, USA., Einstein DJ; Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA., Muranen T; Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA., Corey E; Department of Urology, University of Washington, Seattle, WA, USA., Sharp A; Institute of Cancer Research, Royal Marsden NHS Foundation Trust, London, UK., Balk SP; Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA. sbalk@bidmc.harvard.edu. |
| Source: | Nature communications [Nat Commun] 2025 May 28; Vol. 16 (1), pp. 4931. Date of Electronic Publication: 2025 May 28. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
